Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
Research Abstract |
We have demonstrated in the experiment that anti-EGFR therapy against KRAS-mutated endometrial cancer does not show anti-tumor activity. To target NFkB, the dominant effecter pathway activated downstream of KRAS mutation, seems to be effective strategy to treat KRAS-mutated endometrial cancer
|